The expression of sex steroid receptors and sex steroid-synthesizing/metabolizing enzymes in metastasized lymph nodes of prostate cancer

Nakamura Y 1 , Ise K 2 , McNamara KM 3 , Azmahani A 4 , Sato S 5 , Fujishima F 3 Show all authors , Joh K 3 , Suzuki H 6 , Mitsuzuka K 7 , Arai Y 8 , Takahashi H 5 , Sasano H 3

Affiliations 

  • 1 Division of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Miyagi, Japan; Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan. Electronic address: yasu-naka@tohoku-mpu.ac.jp
  • 2 Division of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Miyagi, Japan; Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan
  • 3 Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan
  • 4 Faculty of Health Sciences, University Sultan Zainal Abidin, Kuala Nerus, Terengganu 21300, Malaysia
  • 5 Department of Pathology, The Jikei University School of Medicine, Tokyo 105-8461, Japan; Department of Pathology, The Jikei University Hospital, Tokyo 105-8471, Japan
  • 6 Department of Pathology and Laboratory Medicine, Sendai Medical Center, Sendai 983-8520, Miyagi, Japan
  • 7 Department of Urology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Miyagi, Japan
  • 8 Department of Urology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Miyagi, Japan; Division of Urology, Miyagi Cancer Center, Natori, Miyagi 981-1293, Japan
Hum Pathol, 2019 02;84:124-132.
PMID: 30290162 DOI: 10.1016/j.humpath.2018.09.011

Abstract

The expression statuses of sex steroid receptors and sex steroid-synthesizing/metabolizing enzymes have been reported in primary prostate cancer lesions, but that in metastatic lymph nodes has remained unknown. Therefore, in this study, we immunolocalized these proteins in primary tumors and paired metastatic lymph nodes of prostate cancer and correlated the findings with clinicopathological factors of individual patients. The expression statuses of AR and ER β was significantly increased in metastatic lymph nodes compared with primary lesions, whereas that of 17βHSD1, 17βHSD2, 17βHSD5, and STS immunoreactivity was decreased in metastatic lymph nodes. In metastatic lymph nodes, the status of 5α2 was significantly correlated with that of AR. In addition, 17βHSD5-, 5α1-, STS-, and EST-positive cases were significantly associated with Gleason score (GS) status (GS > 8 versus GS < 7) in metastatic lymph nodes. Results of our present study did demonstrate that in situ androgen and estrogen metabolism and action play roles in pathophysiology of prostate cancer in metastatic lymph nodes, but these steroidogenic effects could be different from those in primary lesions.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications